XORTX Therapeutics (XRTX) Payables (2020 - 2026)
XORTX Therapeutics' (XRTX) quarterly Payables came in at $845932.0 in Q1 2026, up 14.05% YoY from $741688.0 in Q1 2025, and up 50.58% on a QoQ basis from $561784.0 in Q4 2025.
XORTX Therapeutics (XRTX) Payables (2020 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 7 years of Payables data on file, last reported at $845932.0 in Q1 2026.
- Quarterly Payables rose 14.05% year-over-year to $845932.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $845932.0 (up 14.05% YoY) and the FY2025 annual result came in at $561784.0, down 21.89% from the prior year.
- Payables improved to $845932.0 in Q1 2026, from $561784.0 in the prior quarter.
- In the past five years, Payables ranged from a high of $5.3 million in Q4 2022 to a low of $525245.0 in Q3 2023.
- A 5-year average of $2.0 million and a median of $1.3 million in 2024 frame the typical range for Payables.
- Annual changes were most pronounced in 2023 — Payables plunged 83.4% — and 2024, when it jumped 215.14%.
- Tracing XRTX's Payables over 5 years: stood at $5.3 million in 2022, then slumped by 90.07% to $525245.0 in 2023, then soared by 36.93% to $719205.0 in 2024, then dropped by 21.89% to $561784.0 in 2025, then jumped by 50.58% to $845932.0 in 2026.
- The last three Payables figures came in at $845932.0 (Q1 2026), $561784.0 (Q4 2025), and $778314.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - | 845,932.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 845,932.00 |
| Dec 31, 2025 | 561,784.00 |
| Sep 30, 2025 | 778,314.00 |
| Jun 30, 2025 | 630,982.00 |
| Mar 31, 2025 | 741,688.00 |
| Dec 31, 2024 | 719,205.00 |
| Sep 30, 2024 | 1.66 Mn |
| Jun 30, 2024 | 2.01 Mn |
| Mar 31, 2024 | 3.55 Mn |
| Sep 30, 2023 | 525,245.00 |
| Dec 31, 2022 | 5.29 Mn |
| Sep 30, 2022 | 3.16 Mn |
| Jun 30, 2022 | 2.87 Mn |
| Mar 31, 2022 | 3.98 Mn |
| Dec 31, 2021 | 4.20 Mn |
| Sep 30, 2021 | 9.59 Mn |
| Dec 31, 2020 | 793,297.91 |